Q1 revenue rose 24% to $230 million from $186 million a year earlier. Shares of Telix Pharmaceuticals gained about 5% on the results, reflecting a positive market reaction to the top-line growth.
Q1 revenue rose 24% to $230 million from $186 million a year earlier. Shares of Telix Pharmaceuticals gained about 5% on the results, reflecting a positive market reaction to the top-line growth.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
